What are the recommended dosing regimens of sertraline (Zoloft) for adults with depression or anxiety, panic disorder, obsessive‑compulsive disorder, children and adolescents with OCD, and for elderly or hepatic‑impaired patients?

Sertraline (Zoloft) Dosing Recommendations

Adults with Major Depressive Disorder

Start sertraline at 50 mg once daily and titrate in 25–50 mg increments weekly as needed, up to a maximum of 200 mg/day. 1

• The 50 mg starting dose is both the initial and typically effective therapeutic dose for most patients with depression 1, 2
• If inadequate response after 2–4 weeks, increase by 25–50 mg increments at weekly intervals 1
• The therapeutic range is 50–200 mg/day 1, 2
• Given sertraline's 24-hour elimination half-life, wait at least one week between dose changes 1
• Administer as a single daily dose at any time of day 2

---

Adults with Panic Disorder, PTSD, or Social Anxiety Disorder

Begin at 25 mg once daily to minimize early behavioral activation, then increase to 50 mg after one week. 1, 3

• The lower 25 mg starting dose reduces the risk of transient anxiety worsening that commonly occurs in the first 2–4 weeks 3, 4
• After one week at 25 mg, increase to 50 mg daily 1
• Subsequent increases of 25–50 mg can be made weekly if needed, up to 200 mg/day maximum 1
• Slow titration with 1–2 week intervals between increases is recommended to avoid dose-related agitation 3, 5

---

Adults with Obsessive-Compulsive Disorder

Start at 50 mg once daily and titrate weekly in 25–50 mg increments up to 200 mg/day based on response. 1, 6

• The initial 50 mg dose is appropriate for most adults with OCD 1
• Therapeutic range is 50–200 mg/day 1, 6
• Studies demonstrate efficacy across this dose range, with some patients requiring higher doses for optimal response 6, 7
• Maximum benefit typically emerges by week 12 or later 3

---

Children and Adolescents with OCD (Ages 6–17)

Sertraline is FDA-approved for pediatric OCD only; start children ages 6–12 at 25 mg daily and adolescents ages 13–17 at 50 mg daily. 1, 8

• Ages 6–12 years: Start 25 mg once daily, titrate to 50–200 mg/day as needed 1, 8
• Ages 13–17 years: Start 50 mg once daily, titrate to 50–200 mg/day as needed 1, 8
• Increase in 25–50 mg increments weekly based on tolerability 1
• At low doses (50 mg/day), many youth exhibit a shortened half-life (15 hours) and may require twice-daily dosing; at higher doses (100–150 mg/day), once-daily dosing is usually sufficient 3
• Close monitoring for suicidality is mandatory during the first months of treatment and after any dose adjustment (FDA black-box warning for patients under age 24) 1, 5, 3

Off-Label Use in Adolescent Depression

• For adolescents with major depressive disorder (off-label), start at 25 mg once daily, increase by 12.5–25 mg increments as tolerated, aiming for 50 mg/day with a maximum of 200 mg/day 3

---

Elderly Patients

No dose reduction is required based on age alone; use standard adult starting doses. 3, 2, 9

• Start at 50 mg daily for depression or OCD, or 25 mg daily for panic disorder, PTSD, or social anxiety 1, 2
• The maximum recommended dose remains 200 mg/day 3, 9
• Sertraline is generally well tolerated in older adults and lacks the anticholinergic effects of tricyclic antidepressants 9
• Sertraline has a low potential for drug interactions compared to other SSRIs, which is particularly advantageous in elderly patients on multiple medications 9

---

Patients with Hepatic Impairment

For mild hepatic impairment (Child-Pugh 5–6), reduce both the starting dose and therapeutic range by half. 1

• Mild impairment: Start at 25 mg daily (instead of 50 mg) for depression/OCD, or 12.5 mg daily (instead of 25 mg) for anxiety disorders; maximum 100 mg/day 1
• Moderate (Child-Pugh 7–9) or severe (Child-Pugh 10–15) impairment: Sertraline is not recommended 1

---

Premenstrual Dysphoric Disorder (PMDD)

Start at 50 mg daily, administered either continuously throughout the menstrual cycle or intermittently during the luteal phase only. 1

Continuous Dosing

• Begin at 50 mg daily every day of the cycle 1
• If inadequate response, increase by 50 mg increments per cycle up to 150 mg/day 1

Intermittent Dosing

• Start 50 mg daily beginning 14 days before anticipated menses, continue through onset of menses 1
• If inadequate response, increase to 50 mg/day for the first 3 days of dosing, then 100 mg/day for the remaining days (maximum 100 mg/day) 1

---

Critical Safety Considerations

Screening Before Initiation

• Screen all patients for personal or family history of bipolar disorder, mania, or hypomania before starting sertraline 1

Monitoring Requirements

• Assess patients within 1–2 weeks of starting treatment to screen for suicidality, behavioral activation, and early adverse effects 3, 4
• Close monitoring for suicidal thoughts and behaviors is required, especially in patients under age 24, during the first months of treatment and after dose changes 1, 5, 3
• Telephone follow-up is as effective as in-person visits for detecting adverse events 3
• If no adequate response by 6–8 weeks, consider treatment modification 3, 4
• Expect clinically meaningful improvement around week 6, with maximal benefit by week 12 3, 4

Drug Interactions

• Absolute contraindication: Concurrent use with MAOIs due to serotonin syndrome risk; allow at least 14 days between discontinuing an MAOI and starting sertraline, and vice versa 1, 3
• Sertraline may inhibit CYP2D6; use caution with drugs metabolized by this pathway 3
• Concurrent aspirin or NSAIDs increase the risk of abnormal bleeding 3
• When co-administered with bile-acid sequestrants (e.g., cholestyramine), give sertraline at least 4 hours apart 3

Discontinuation

• Taper sertraline gradually over 10–14 days rather than stopping abruptly to minimize discontinuation syndrome (dizziness, fatigue, nausea, insomnia, sensory disturbances, anxiety) 1, 3, 4

---

Common Adverse Effects

• Gastrointestinal: nausea, diarrhea, dry mouth, constipation 3, 9
• Neurological: headache, dizziness, tremor 3, 9
• Sleep-related: insomnia, somnolence 3, 9
• Other: sweating, appetite changes, weight fluctuations, sexual dysfunction 3, 9
• Behavioral activation/agitation (motor restlessness, insomnia, impulsivity) is more common in younger children and anxiety disorders; it typically emerges early in treatment or with dose increases 5, 3

---

Dose-Response Considerations

• Higher doses do not guarantee greater efficacy and increase the risk of adverse effects 3, 4
• The 50 mg dose is optimal for most patients when balancing efficacy and tolerability 2
• Therapeutic benefit follows a logarithmic pattern: statistically significant improvement may appear within 2 weeks, but clinically meaningful improvement requires approximately 6 weeks, with maximal response by week 12 or later 3, 5